TWEAK and its receptor Fn14 in the synovium of patients with rheumatoid arthritis compared to psoriatic arthritis and its response to tumour necrosis factor blockade
van Kuijk, A.W.R.; Wijbrandts, C.A.; Vinkenoog, M.; Zheng, T.S.; Reedquist, K.A.; Tak, P.P.

Published in: Annals of the Rheumatic Diseases

DOI: 10.1136/ard.2008.090548

Citation for published version (APA):
TWEAK and its receptor Fn14 in the synovium of patients with rheumatoid arthritis compared to psoriatic arthritis and its response to tumour necrosis factor blockade

A W R van Kuijk,1 C A Wijbrandts,1 M Vinkenoog,1 T S Zheng,2 K A Reedquist,1 P P Tak1

ABSTRACT

Objective: To investigate the expression of tumour necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) and its receptor fibroblast growth factor inducible 14 (Fn14) in the inflamed synovium of patients with arthritis, as TWEAK blockade has been observed to have a beneficial effect in an animal model of rheumatoid arthritis (RA).

Methods: Synovial tissue (ST) biopsies were obtained from 6 early, methotrexate-naive patients with RA as well as 13 patients with RA and 16 patients with psoriatic arthritis (PsA) who were matched for treatment and disease duration. Serial ST samples were obtained from a separate cohort of 13 patients with RA before and after infliximab treatment. TWEAK and Fn14 expression was evaluated by immunohistochemistry and digital image analysis.

Results: TWEAK and Fn14 were clearly expressed in ST of patients with RA and PsA. TWEAK expression was significantly higher in RA (sublining samples compared to PsA (p = 0.005 and p = 0.014, respectively), but Fn14 expression was comparable. Double immunofluorescence showed TWEAK and Fn14 expression on fibroblast-like synoviocytes and macrophages, but not T cells. Of interest, persistent TWEAK and Fn14 expression was found after anti-TNF therapy.

Conclusions: TWEAK and Fn14 are abundantly expressed in the inflamed synovium of patients with RA and PsA. This raises the possibility that blocking TWEAK/Fn14 signalling could be of therapeutic benefit in inflammatory arthritis.

Tumour necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) is a TNF ligand superfamily member that mediates pleiotropic effects on a variety of cells via its receptor, fibroblast growth factor inducible 14 (Fn14). The TWEAK/Fn14 pathway appears to have a physiological role in the regulation of tissue repair after injury, when Fn14 expression is highly induced. Fn14 can be expressed by many cell types, including epithelial, mesenchymal and endothelial cells, and progenitor cells of the mesenchymal lineage. Activating Fn14 can have a number of effects, depending on cell type and context, including proangiogenic effects and induction of fibroblast-like synoviocytes (FLS) to produce proinflammatory cytokines and chemokines, such as interleukin (IL)6, IL8 and regulated on activation, normal T expressed and secreted (RANTES). TWEAK may also promote bone and cartilage destruction through inhibition of chondrogenesis and osteogenesis and promotion of osteoclastogenesis.

These data raise the possibility that TWEAK may contribute to chronic synovitis, a notion supported by the observation that TWEAK expression is dramatically elevated in the murine collagen-induced arthritis (CIA) model of arthritis. Blocking TWEAK signalling reduced the severity of arthritis in this model, and diminished synovial inflammation, vascularity, and cartilage and bone destruction. However, very little is known about the role of the TWEAK/Fn14 pathway in human inflammatory arthritis. To address this issue, we examined the expression of TWEAK and Fn14 in synovial tissue (ST) of patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA), in newly diagnosed, previously untreated patients with RA, and in patients with RA on methotrexate before and after treatment with infliximab.

PATIENTS AND METHODS

Patients and synovial tissue acquisition

For a comparative analysis of TWEAK and Fn14 expression, ST biopsies were obtained by arthroscopy from 15 patients with RA and 16 patients with PsA with clinically active arthritis. ST biopsies from a second cohort of 15 patients with RA on methotrexate (MTX) therapy were obtained from the same joint before and 4 weeks after the initiation of infliximab (IFX) therapy (IFX 3 mg/kg, administered intravenously at baseline and 2 weeks later). Additionally, ST biopsies were obtained from 6 patients newly diagnosed as having RA who had not been treated with any disease-modifying antirheumatic drug (DMARD). All patients with RA met the 1987 revised criteria of the American College of Rheumatology for the diagnosis of RA. All patients with PsA met the CASPAR (for “ClASsification of Psoriatic Arthritis”) group criteria, and had active joint and skin disease at the time of arthroscopy. ST biopsies were obtained by arthroscopy from an actively inflamed knee, ankle or wrist joint under local anaesthesia. Biopsies were obtained from six or more sites in each joint. ST biopsies were immediately embedded in TissueTek OCT (Miles Diagnostics, Elkhart, Indiana, USA), snap frozen in liquid nitrogen and stored at −80°C, as previously described in detail. All patients provided their written informed consent and patient clinical and demographic data were obtained before arthroscopy. This study was approved by the local medical ethics committee.
**Immunohistochemistry and digital image analysis**

ST samples were cut with a cryostat (5 μm), fixed with acetone, and endogenous peroxidase activity was blocked with 0.3% hydrogen peroxide. Specific monoclonal antibodies were used to detect TWEAK (clone P3H8) and Fn14 (clone P2D3) (both from Biogen Idec, Cambridge, Massachusetts, USA). Bound antibody was detected with a three-step immunoperoxidase method using a biotinylated tyramine amplification method. Stained sections were then randomly analysed using digital image analysis (DIA), as previously described in detail. Expression of TWEAK and Fn14 is presented as integrated optical density (IOD)/mm², an arbitrary unit representing the amount of staining per mm².

**Double immunofluorescence**

TWEAK and Fn14 expression in distinct synovial cell populations was assessed by double immunofluorescence in 15 randomly selected patients (8 with PsA and 7 with RA). Sections were incubated overnight at 4°C with primary monoclonal antibodies against TWEAK and Fn14, and then labelled with streptavidin-ALEXA 594 (Invitrogen/Molecular Probes, Breda, The Netherlands) for 30 min. Next, sections were blocked with 10% normal mouse serum, incubated for 30 min with fluorescein isothiocyanate (FITC)-labelled markers for CD55 (clone BRIC 110, Sanquin, Amsterdam, The Netherlands), CD3 (clone SK7, Becton Dickinson, San Jose, California, USA) and CD68 (clone KP1, Dako, Glostrup, Denmark). Patients with RA were more often RF and/or anti-CCP positive than patients with PsA. No other significant differences in the clinical data between patients with RA and PsA were detectable.

**Table 1** Demographic data of the first cohort of patients with psoriatic arthritis (PsA) and rheumatoid arthritis (RA)

<table>
<thead>
<tr>
<th></th>
<th>PsA (n = 16)</th>
<th>RA (n = 13)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female, no (%)</td>
<td>6 (38%)</td>
<td>6 (46%)</td>
</tr>
<tr>
<td>Age in years, mean (range)</td>
<td>46.5 (22–64)</td>
<td>52.6 (38–69)</td>
</tr>
<tr>
<td>Disease duration in months, mean (range)</td>
<td>120 (39–284)</td>
<td>137 (10–278)</td>
</tr>
<tr>
<td>RF and/or anti-CCP positive, no (%)</td>
<td>2 (13%)</td>
<td>13 (100%)</td>
</tr>
<tr>
<td>Erosions, no (%) of patients</td>
<td>8 (50%)</td>
<td>11 (88%)</td>
</tr>
<tr>
<td>ESR mm/h, median (IQR)</td>
<td>21.5 (7.3–32.3)</td>
<td>28.0 (9.5–47.5)</td>
</tr>
<tr>
<td>CRP mg/litre, median (IQR)</td>
<td>10.4 (2.5–23.7)</td>
<td>7.0 (3.5–35.5)</td>
</tr>
<tr>
<td>Methotrexate dose (mg), mean (SD)</td>
<td>16.7 (7.2)</td>
<td>20.0 (4.3)</td>
</tr>
</tbody>
</table>

Patients with RA were more often RF and/or anti-CCP positive than patients with PsA. No other significant differences in the clinical data between patients with RA and PsA were detectable.

**CCP, cyclic citrullinated peptide; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; IQR, interquartile range (25th–75th percentile); RF, rheumatoid factor.**

**Figure 1** Representative photographs showing tumour necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) expression (reddish-brown staining) in rheumatoid arthritis (RA) synovial tissue (ST) (a–c) and psoriatic arthritis (PsA) ST (d–f). Overview of RA ST (a) (original magnification 100×), and close up of the intimal lining layer (b) and the synovial sublining with (peri)vascular staining (c) (magnification 200×); overview of PsA ST (d), and close up of the intimal lining layer (e) and the synovial sublining with (peri)vascular staining (f).
Denmark), covered with VectaShield mounting medium (H-1200, Vector laboratories, Burlingame, California, USA), and analysed with a wide-field upright microscope (Leica DMRA, Wetzlar, Germany) coupled to a CCD camera and Image-Pro Plus software (Media Cybernetics, Dutch Vision Components, Breda, The Netherlands). Coexpression of CD68, CD55 and CD3 with TWEAK and Fn14 was determined by the manual counting of positive cells by two independent blinded observers (Tom Smeets and Dion Groot, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands).

**Statistical analysis**

To compare the differences in expression of TWEAK and Fn14 between groups the Mann–Whitney U test for non-parametric data was used. Correlations were assessed using the Spearman rank correlation coefficient. Serial biopsies were evaluated using the Wilcoxon signed rank test. A p value of <0.05 was considered statistically significant.

**RESULTS**

Table 1 shows the patient characteristics of the first patient cohort (13 patients with RA and 16 with PsA) who were used for cross sectional comparison. All these patients were treated with methotrexate; there was a trend towards slightly higher dosages in RA, but this difference was not statistically significant. In both groups one patient was also treated with prednisolone 10 mg daily. Most patients had longstanding disease and displayed comparable erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels, indicating similar degrees of inflammatory activity.

In RA and PsA ST, strong expression of TWEAK was observed in the intimal lining layer and the synovial sublining, including perivascular regions in a subset of blood vessels (fig 1). Expression of TWEAK was higher in RA than in PsA in the intimal lining layer (median and interquartile range (IQR), respectively 45 305 (21 410–63 456) versus 14 381 (934–20 002) IOD/mm² (p = 0.005) and the synovial sublining 44 941 (30 687–106 183) versus 8022 (2484–70 439) IOD/mm² (p = 0.014). Fn14 was expressed in the intimal lining layer and the perivascular regions of the synovial sublining (fig 2). Fn14 expression was not significantly different between RA and PsA. Immunofluorescent double staining revealed frequent TWEAK (65%) and Fn14 (46%) expression in CD55+ RA FLS. CD68+ macrophages also frequently expressed TWEAK (46%) and Fn14 (20%). In contrast, CD3+ T cells hardly expressed any TWEAK or Fn14.
A second cohort of 15 patients with RA underwent arthroscopy before and 4 weeks after initiation of infliximab infusions. Patients had longstanding disease (mean disease duration 127 months, range 10–311), all were treated with MTX (mean dose 15 mg/week, range 5–30) and 10/15 with prednisolone (mean dose 9 mg/day, range 2.5–15). The 28-joint Disease Activity Score (DAS28) was significantly reduced following 4 weeks of infliximab therapy: DAS28 (median and IQR) at baseline, 6.25 (5.57–7.04); after 4 weeks, 4.48 (3.82–5.98) (p<0.01). However, there was persistent TWEAK expression after TNF blockade without any significant changes in ST TWEAK or Fn14 expression following infliximab therapy.

To rule out the possibility that the expression of TWEAK and Fn14 had been influenced considerably by disease duration or DMARD treatment in the above mentioned cohorts, ST samples from a third cohort of 6 recently diagnosed patients with RA who had not yet been treated with DMARDs was studied and compared to the 15 patients with RA from the second cohort. The expression of TWEAK and Fn14 was comparable between this group with early disease and the abovementioned group with longstanding disease before start of infliximab therapy, indicating that TWEAK and its receptor are expressed in early RA.

**DISCUSSION**

TWEAK and Fn14 are both abundantly expressed in the inflamed synovium of patients with (early) RA and PsA, where they may promote synovial inflammation and joint destruction. Of importance, there is persistent expression of TWEAK and its receptor after TNF blockade. TWEAK expression in the intimal lining layer and synovial sublining is significantly higher in RA compared to PsA, while Fn14 expression is similar. TWEAK and Fn14 are mainly expressed by FLS and, to a lesser extent, macrophages, suggesting that both effector cells may participate in TWEAK responses in patients with arthritis.

The TWEAK/Fn14 pathway appears to have a physiological role in the regulation of tissue repair after injury. TWEAK may initially be produced by tissue cells, and by invading inflammatory cells such as monocytes. The TWEAK-Fn14 pathway might then drive chemokine and cytokine production, resulting in additional infiltration of proinflammatory cells, and facilitate angiogenesis and the proliferation of progenitor cells needed for tissue repair. Chronic expression of TWEAK and Fn14 in inflammatory arthritis may subvert processes beneficial in acute tissue repair to pathogenic contributions. The expression of TWEAK and Fn14 in chronic synovitis could contribute to persistent inflammation and progressive destruction of the joint tissue by the production of chemokines, cytokines and MMPs, and promotion of cell proliferation and angiogenesis. Because the TWEAK/Fn14 pathway does not appear to be involved in the regulation of adaptive immunity, it has been suggested that blocking TWEAK/Fn14 activation would potentially have a favourable safety profile. Further studies are needed to identify the contributions of TWEAK/Fn14 to inflammatory arthritis, and the therapeutic potential of targeting this pathway.

**Acknowledgements:** The authors wish to thank Dr Tom JM Smeets and Dion Groot for their work on the immunohistochemical staining and immunofluorescent double staining.

**Funding:** This study was supported by Biogen Idec, Cambridge, Massachusetts, USA. This research was also supported by the European Community’s FP6 funding (“Autocure”). This publication reflects only the author’s views; the European Community is not liable for any use that may be made of the information herein.

**Competing interests:** TSZ is an employee of Biogen Idec, Cambridge, Massachusetts, USA.

**Ethics approval:** Ethics approval was granted by the Medical Ethics Committee of the Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands.

**Provenance and peer review:** Not commissioned; externally peer reviewed.

**REFERENCES**

TWEAK and its receptor Fn14 in the synovium of patients with rheumatoid arthritis compared to psoriatic arthritis and its response to tumour necrosis factor blockade

A W R van Kuijk, C A Wijbrandts, M Vinkenoog, et al.

*Ann Rheum Dis* 2010 69: 301-304 originally published online January 15, 2009
doi: 10.1136/ard.2008.090548

Updated information and services can be found at:
http://ard.bmj.com/content/69/01/301.full.html

These include:

**References**
This article cites 13 articles, 3 of which can be accessed free at:
http://ard.bmj.com/content/69/01/301.full.html#ref-list-1

**Open Access**
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/
Articles on similar topics can be found in the following collections

- **Unlocked** (160 articles)
- **Degenerative joint disease** (2463 articles)
- **Musculoskeletal syndromes** (2657 articles)
- **Connective tissue disease** (2207 articles)
- **Immunology (including allergy)** (2568 articles)
- **Rheumatoid arthritis** (1670 articles)
- **Pathology** (225 articles)
- **Clinical diagnostic tests** (764 articles)
- **Radiology** (695 articles)
- **Surgical diagnostic tests** (228 articles)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/